EDSA
Edesa Biotech, Inc.
Key Financials
Operating Income
$-7911566
↓ 12.8%
Net Income
$-7185523
↓ 16.5%
Revenue
$0
↓ 100.0%
EPS (Diluted)
$-0.57
↓ 58.3%
Total Assets
$13.5M
↑ 254.8%
Total Liabilities
$1.8M
↓ 0.5%
Cash & Equivalents
$10.8M
↑ 980.0%
Shareholders' Equity
$12.5M
↑ 528.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| EFFECT | 7/13/2026 | View on SEC |
| 424B3 | 7/13/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| S-3 | 7/2/2026 | View on SEC |
| D | 6/26/2026 | View on SEC |
| SCHEDULE 13G | 6/18/2026 | View on SEC |
| SCHEDULE 13D/A | 6/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EDSA |
| Company Name | Edesa Biotech, Inc. |
| CIK | 1540159 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0930 |
| State of Incorporation | A1 |
| Phone | (905) 475-1234 |